Ipilimumab is a standard therapy for advanced melanoma. Severe immune related adverse events occur in up to 30% of patients and require treatment with immunosuppressants such as steroids or the anti-TNFα antibody, infliximab. We describe two patients with advanced melanoma treated with ipilimumab. Both suffered from severe immune related side effects and required prolonged immunosuppression with steroids and/or infliximab. Both patients recovered and in spite of the immune suppression, demonstrate clinical evidence of tumor control. This argues that distinct immunological effector functions control nosocomial infection and tumor, respectively. To our knowledge, these are also the first two case reports of pneumocystis pneumonia in this setting.
The development of vitreous and retinal metastases despite a systemic response to ipilimumab identifies the challenge of immunotherapy in an immune privileged site. Treatment is challenging, and outcomes are variable. A local approach of bilateral pars plana vitrectomy, external beam radiotherapy, and subsequent bilateral cataract surgery provided an excellent visual result with no recurrence at 12 months.
Aims: Evidence suggests that the presence of tumour necrosis is an adverse prognostic factor in renal cell carcinoma (RCC). However, it has also been shown that tumour regression, a microscopic feature associated with necrosis, may be a favourable short term prognostic factor in RCC. Methods: Pathology reports of 253 RCCs from 1992 to 2001 were reviewed, and identified 37 tumours with substantial macroscopic or microscopic necrosis. Microscopic pathology, TNM 1997 tumour stage, and clinical follow up were reviewed and correlated with pathological findings. Three cases were rejected because two were diagnosed at necropsy, and a third was the result of renal arterial embolisation. Results: Twenty of the 34 cases showed ,50% necrosis, 10 showed 50-94% tumour necrosis, and four showed .95% tumour necrosis. Follow up data were unavailable in three cases. Nine of the remaining 31 tumours progressed; six were group 3 tumours showing ,50% necrosis, three were group 2 tumours showing 50-94% necrosis, and none was a group 1 tumour showing .95% necrosis. Conclusions: Extensive necrosis (.95% necrosis) is rare in RCC, accounting for only 1.6% of those diagnosed during eight years in this unselected hospital series. The microscopic pattern of necrosis was typical, requiring extensive tumour sampling for definitive tumour diagnosis. Although there were only four patients with extensive necrosis, none developed recurrent or metastatic carcinoma, or died from RCC. Although extensive (.95%) necrosis may imply better short term prognosis after adjusting for tumour pathological TNM stage, it is probably not a prognostic variable in RCC. and any evidence of tumour necrosis. 1 2 5-8 However, the importance of extensive necrosis, which is rare in RCC, is not entirely clear.9 10 A recent study suggested that RCC with very extensive necrosis may be capable of aggressive behaviour. 8Necrosis is commonly seen in RCC and necrosis has been shown to be an adverse prognostic factor in certain subtypes of RCC, if any necrosis at all is present in the tumour sections.1 2 5-8The pathology reports of all cases of RCC diagnosed over an eight year period were retrieved from our laboratory files to identify tumours showing extensive necrosis. The clinical follow up data of these patients were then obtained. MATERIALS AND METHODSThe pathology reports of all 253 RCCs diagnosed between 1992 and 2001 at the department of pathology at Queen Alexandra Hospital, Portsmouth, UK, were reviewed after they were identified by searching the laboratory computer database using a SNOMED search for all RCCs. We identified 37 tumours where the pathologist had commented that there was evidence of either macroscopic or microscopic necrosis at the time of originally reporting the case. The gross descriptions and all available slides from these 37 cases were then reviewed in detail, without prior knowledge of the clinical follow up data or patient prognostic information. The overall percentage of necrosis in each case was assessed from all the available haematoxylin and...
SummaryIn the present study, we investigated the expression of Mcl-1 and Bcl-2 by immunohistochemistry in 85 patients of grades 1-3 and transformed follicular lymphoma (FL)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.